Skip to content
Review Open access

Efficacy and Safety of PD‐1/PD‐L1 Inhibitors Combined With Anti‐Angiogenic Tyrosine Kinase Inhibitors for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Systematic Review and Single‐Arm Meta‐Analysis

Sep 2026 · Cancer Medicine · Vol 15 · 0 citations · 35 references
Medicine

Abstract

To evaluate the efficacy and safety of PD‐1/PD‐L1 inhibitors plus small‐molecule anti‐angiogenic drugs (apatinib, anlotinib and famitinib) for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.